6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Pivot, X; Romieu, G; Debled, M; Pierga, Y; Kerbrat, P; Bachelot, T; Lortholary, A; Espie, M; Fumoleau, P; Serin, D; Jacquin, JP; Jouannaud, C; Rios, M; Abadie-Lacourtoisie, S; Venat-Bouvet, L; Cany, L; Catala, S; Khayat, D; Gambotti, L; Pauporte, I;

Pivot, X (reprint author), Ctr Paul Strauss, F-67065 Strasbourg, France.

LANCET, 2019; 393 (10191): 2591

Abstract

Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 m......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索